Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based Hengrui Pharma, writes the company in a press release.
The $500 million collaboration unlocks the potential for up to 12 new treatments, bolstering GSK’s pipeline well beyond 2031. The partnership will put a strong focus on respiratory diseases, inflammation, and cancer.
At the center of the deal is a promising new drug, HRS-9821 which treats COPD. Unlike standard therapies, this one combines PDE3 and PDE4 inhibition for better bronchodilation and inflammation control. It is also designed to be delivered via a dry-powder inhaler.
The deal grants GSK exclusive global rights to HRS-9821 outside of China and a few surrounding territories. It also positions the company to serve a broader population of COPD patients, including those who don’t respond well to steroids.
Beyond HS-9821, the agreement sets the stage for up to 11 additional early-stage therapies. Hengrui will lead initial development, this GSK able to take over after Phase 1 trials.
With Montco serving as home base for much of GSK’s U.S. operations, this strategic alliance brings exciting implications for local biotech and global patient care.
Read more about the exciting new partnership between Glaxosmithkline and China’s Hengrui Pharma at GSK.
Editor’s Note: This post was originally published on MONTCO.Today in July 2025.
